Magnetically softened iron oxide (MSIO) nanofluid and its application to thermally-induced heat shock proteins for ocular neuroprotection. (September 2016)

• Record Type: Journal Article
• Authors: Bae, Seongtae; Jeoung, Jin Wook; Jeun, Minhong; Jang, Jung-tak; Park, Joo Hyun; Kim, Yu Jeong; Lee, Kwan; Kim, Minkyu; Lee, Jooyoung; Hwang, Hey Min; Paek, Sun Ha; Park, Ki Ho
• Is Part Of: Biomaterials. Volume 101(2016)
• Page Start: 165
• Page End: 175
• Publication Date: 2016-09
• Subjects: Magnetic nanofluid hyperthermia (MNFH) -- Magnetically softened iron oxide (MSIO) -- (Mn0.5Zn0.5)Fe2O4 nanoparticles -- Heat shock proteins -- Ocular neuroprotection; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2016.05.049
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Magnetically softened iron oxide (MSIO) nanofluid, PEGylated (Mn0.5 Zn0.5 )Fe2 O4, was successfully developed for local induction of heat shock proteins (HSPs) 72 in retinal ganglion cells (RGCs) for ocular neuroprotection. The MSIO nanofluid showed significantly enhanced alternating current (AC) magnetic heat induction characteristics including exceptionally high SLP (Specific Loss Power, > 2000 W/g). This phenomenon was resulted from the dramatically improved AC magnetic softness of MSIO caused by the magnetically tailored Mn 2+ and Zn 2+ distributions in Fe3 O4 . In addition, the MSIO nanofluid with ultra-thin surface coating layer thickness and high monodispersity allowed for a higher cellular uptake up to a 52.5% with RGCs and enhancing "relaxation power" for higher AC heating capability. The RGCs cultured with MSIO nanofluid successfully induced HSPs 72 by magnetic nanofluid hyperthermia (MNFH). Moreover, it was interestingly observed that systematic control of "AC magnetically-induced heating up rate" reaching to a constant heating temperature of HSPs 72 induction allowed to achieve maximized induction efficiency at the slowest AC heating up rate during MNFH. In addition to in-vitro experimental verification, the studies of MSIO infusion behavior using animal models and a newly designed magnetic coil system demonstrated that the MSIO has promising biotechnical feasibility for thermally-induced HSPs agents in future glaucoma clinics.